Fig. 5: Rewiring of multicellular ecosystems in cancer.
From: Cross-tissue multicellular coordination and its rewiring in cancer
a, Overview of the pan-cancer single-cell atlas. b, Expression of signature genes for cancer-associated cell subsets. c, Overview of multicellular analysis in cancer. d, Sample-averaged activities of dominant healthy CMs in healthy, adjacent non-tumour, and tumour samples across cancer types (Methods). CESC, cervical squamous cell carcinoma; col., colon; CRC, colorectal cancer; cSCC, cutaneous squamous cell carcinoma; HCC, hepatocellular carcinoma; HNSC, head and neck squamous cell carcinoma; KIRC, kidney renal clear cell carcinoma; LUAD, lung adenocarcinoma; ora.muc., oral mucosa; OV, ovarian cancer; rec., rectum. e, CM03 activities in CRC (left) and CM08 activities in HNSC (right) across healthy, adjacent non-tumour and tumour samples. Dots represent individual samples. Colon/rectum-CRC: healthy, n = 16; adjacent, n = 51; tumour, n = 132. Oral mucosa-HNSC: healthy, n = 23; adjacent, n = 27; tumour, n = 73. Two-tailed unpaired Wilcoxon tests. f, Left, heat map showing the co-occurrence of cell-subset pairs in individual cancer types (Methods). Right, bar plot showing the number of cancer types in which individual pairs are detected. Only pairs detected in at least three cancer types are shown. g, Sample-averaged cCM02 activities in healthy, adjacent non-tumour and tumour samples across cancer types (Methods). h, cCM02 activities in CRC (left) and HNSC (right) across healthy, adjacent non-tumour and tumour samples. Dots represent individual samples, matching those in e. Two-tailed unpaired Wilcoxon tests. i, Dynamics of the co-occurring cCM02 network during tumour progression (Methods). j, Differential expression of the cCM02 programme between tumour and adjacent non-tumour samples across TCGA cancer types. BLCA, bladder urothelial carcinoma; BRCA, breast cancer; COAD, colon adenocarcinoma; ESCA, oesophageal carcinoma; KICH, kidney chromophobe; KIRP, kidney renal papillary cell carcinoma; LIHC, liver hepatocellular carcinoma; LUSC, lung squamous cell carcinoma; PRAD, prostate adenocarcinoma; STAD, stomach adenocarcinoma; THCA, thyroid carcinoma; UCEC, uterine corpus endometrial carcinoma. k, cCM02 programme expression in pre-invasive lesions with spontaneous regression or progression to cancer outcomes. Two-tailed unpaired Wilcoxon test. For box plots in e,h,k, the centre line represents the median, the box limits delineate the top and bottom quartiles, and the whiskers extend to the highest and lowest values within 1.5× the interquartile range.
